한글목차

세계의 콜레스테롤 검사 제품 시장은 2024년에 198억 5,000만 달러로 평가되었고, 2033년까지는 422억 5,000만 달러에 이를 것으로 예측되며, 예측 기간 2025년에는 CAGR 8.8%로 성장할 전망입니다.

콜레스테롤 검사는 혈액에서 콜레스테롤 수치를 측정하는 데 사용되는 중요한 진단 절차이며 심장 질환, 뇌졸중, 죽상 동맥 경화증과 같은 심혈관 질환의 위험을 평가하는 데 도움이 됩니다. 콜레스테롤 검사 제품은 혈액에서 콜레스테롤 수치를 측정하는 데 사용되는 중요한 도구이며 심혈관 질환의 검출, 예방 및 관리에 중요한 역할을 합니다.

이러한 제품은 전통적인 실험실 기반 키트부터 보다 편리한 포인트 오브 케어 장비 및 가정용 검사 키트에 이르기까지 다양한 형태로 제공되며, 개인과 건강 관리 제공업체 모두 콜레스테롤 수치를 모니터링하기 위해 쉽게 액세스할 수 있습니다. LDL(나쁜 콜레스테롤) 및 HDL(좋은 콜레스테롤)과 같은 주요 성분을 측정함으로써 이러한 제품은 심장 질환의 위험을 평가하고 심장 건강을 개선하기 위한 치료 계획을 안내하는 데 도움이 됩니다. 심장 건강에 대한 인식이 높아짐에 따라 이러한 콜레스테롤 검사 제품에 대한 수요가 증가하고 있으며 예방적이고 적극적인 치료를 지원합니다.

시장 역학 :

촉진요인 및 억제요인

심혈관 질환 발생률 상승

심혈관 질환(CVD)의 환자 수가 증가하는 것은 콜레스테롤 검사 수요를 촉진하는 중요한 요인입니다. 심장병과 뇌졸중이 세계의 주요 사인이기 때문에 심장 건강을 유지하기 위해 콜레스테롤 수치를 억제하는 것이 얼마나 중요한지에 대한 인식이 높아지고 있습니다. 높은 콜레스테롤은 이러한 질병의 주요 원인이기 때문에 정기적인 콜레스테롤 검사는 건강 관리 전문가와 심각한 건강 문제를 예방하고자 하는 개인에게 중요한 단계입니다.

고혈압, 비만, 당뇨병과 같은 관련 질환으로 진단받는 사람들이 늘어남에 따라 신뢰성이 높고 사용하기 쉬운 콜레스테롤 검사 도구에 대한 필요성이 커지고 있습니다. 이러한 의식의 고조와 조기 발견에 대한 주목에 의해 심혈관 장애의 리스크를 낮추기 위해서 콜레스테롤을 감시 및 관리하는 방법을 적극적으로 요구하는 사람이 늘어나, 콜레스테롤 검사 시장은 활성화할 것으로 예상됩니다.

높은 치료비

첨단 콜레스테롤 검사 장비의 고비용은 특히 저소득 지역 및 소규모 의료 제공업체에 있어서 콜레스테롤 검사 제품 시장의 성장을 크게 저해할 수 있습니다. 첨단 콜레스테롤 검사 장비의 대부분은 전문 실험실에서 사용되는 것들과 특별한 케어 검사 장비 등이기 때문에 많은 투자가 필요합니다. 이러한 장비에는 높은 유지 보수 비용, 적절한 사용을 위한 교육의 필요성, 정확성을 보장하기 위한 정기적인 교정의 필요성 등이 수반됩니다.

목차

제1장 조사 방법 및 조사 범위

제2장 정의 및 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 연구개발의 진보
  • 성장 억제요인
    • 치료비 상승
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter's Five Forces 분석
• 공급망 분석
• 가격 분석
• 특허 분석
• 규제 분석
• SWOT 분석
• 언멧 요구

제6장 제품별

• 기기
• 검사 키트
• 기타

제7장 테스트 유형별

• 총 콜레스테롤 검사
• 저밀도 지단백질(LDL) 콜레스테롤 검사
• 고밀도 지단백질(HDL) 콜레스테롤 검사
• 트리글리세리드 검사
• 기타

제8장 용도별

• 심혈관 질환
• 당뇨병
• 비만
• 고지혈증
• 기타

제9장 최종 사용자별

• 병원
• 진단센터
• 재택치료
• 연구실

제10장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제11장 경쟁 구도

• 경쟁 시나리오
• 시황 및 점유율 분석
• M&A 분석

제12장 기업 프로파일

• Abbott Laboratories
  • 기업 개요
  • 제품 포트폴리오
    • 제품 설명
    • 제품의 주요 실적 평가 지표(KPI)
    • 과거 및 예측의 제품 판매
    • 제품 판매량
  • 재무 개요
    • 회사 수익
    • 지역별 수익분배
    • 수익 예측
  • 주요 발전
    • 합병 및 인수
    • 주요 제품 개발 활동
    • 규제 당국의 승인 등
  • SWOT 분석
• F. Hoffmann-La Roche AG
• Siemens Healthineers GmbH
• ACON Laboratories Inc.
• Lepu Medical Technology(Beijing) Co., Ltd.
• SD Biosensor, INC.
• Recombigen Laboratories Pvt. Ltd
• Assure Tech(Hangzhou) Co., Ltd.
• VP Healthcare
• SG Diagnostics
• Processa Pharmaceuticals, Inc.
  • 파이프라인 제품 설명
  • 제품의 주요 실적 평가 지표(KPI)
  • 주요 활동
  • 시장 진입의 타임라인
  • 제품 보급률
  • 매출 예측과 예측
• Vanda Pharmaceuticals Inc.
• Renexxion Ireland Limited
• Aclipse Therapeutics
• 각 시장 진출기업에 대해서도 유사한 데이터가 제공됩니다.

제13장 부록

영문목차

The global cholesterol testing products market reached US$ 19.85 billion in 2024 and is expected to reach US$ 42.25 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.

Cholesterol testing is a vital diagnostic procedure used to measure the levels of cholesterol in the blood, helping to assess the risk of cardiovascular diseases such as heart disease, stroke, and atherosclerosis. Cholesterol testing products are important tools used to measure cholesterol levels in the blood, playing a vital role in detecting, preventing, and managing cardiovascular diseases.

These products come in various forms, from traditional lab-based kits to more convenient point-of-care devices and at-home testing kits, giving both individuals and healthcare providers easy access to monitor cholesterol levels. By measuring key components like LDL (bad cholesterol) and HDL (good cholesterol), these products help evaluate the risk of heart disease and guide treatment plans to improve heart health. With the growing awareness of heart health, the demand for these cholesterol testing products is increasing, supporting proactive and preventive care.

Market Dynamics: Drivers & Restraints

Rising Incidence of Cardiovascular Diseases

The growing number of people affected by cardiovascular diseases (CVDs) is a key factor driving the demand for cholesterol testing. With heart disease and strokes being the leading causes of death around the world, there's a rising awareness about how crucial it is to keep cholesterol levels in check to maintain heart health. High cholesterol is a major contributor to these conditions, making regular cholesterol testing an important step for both healthcare professionals and individuals who want to prevent serious health issues.

As more people are diagnosed with related conditions like high blood pressure, obesity, and diabetes there's a greater need for reliable and easy-to-use cholesterol testing tools. This growing awareness and focus on early detection are expected to boost the cholesterol testing market, with more people actively seeking ways to monitor and manage their cholesterol to lower the risk of cardiovascular problems.

High Costs of Treatment

The high cost of advanced cholesterol testing devices can significantly hinder the growth of the cholesterol testing products market, especially in low-income regions or for smaller healthcare providers. Many advanced cholesterol testing devices, such as those used in professional labs or specialized point-of-care testing equipment, require significant upfront investment. These devices often come with high maintenance costs, training requirements for proper usage, and the need for regular calibration to ensure accuracy.

Segment Analysis

The global cholesterol testing products market is segmented based on procedure type, device type, surgery type, indication, end-user, and region.

Treatment:

Devices segment is expected to dominate the global cholesterol testing products market share

The devices segment is expected to dominate the cholesterol testing products market due to a combination of technological advancements, growing consumer demand for at-home testing, and the increasing focus on preventive healthcare. With innovations in point-of-care testing devices and self-monitoring kits, cholesterol testing has become more accurate, accessible, and convenient, allowing individuals to monitor their cholesterol levels from the comfort of their homes.

The integration of these devices with mobile apps and digital health platforms further enhances their appeal by enabling real-time tracking and personalized health insights. As the shift toward proactive health management continues, cholesterol testing devices are becoming essential tools for both healthcare professionals and consumers, driving widespread adoption and market growth. Their ability to provide quick, reliable results at an affordable cost positions them as the leading solution in the market.

Geographical Analysis

North America is expected to hold a significant position in the global cholesterol testing products market share

North America is leading the cholesterol testing products market due to high levels of awareness about heart health, and a strong emphasis on preventive care. The region benefits from well-established healthcare systems, widespread access to cutting-edge medical devices, and a growing focus on early detection and management of cardiovascular diseases. In addition, both the U.S. and Canada have robust health insurance systems that often cover the cost of cholesterol testing, making it more accessible to the general population.

The increasing prevalence of high cholesterol, coupled with rising healthcare awareness campaigns, has driven the adoption of cholesterol testing products, further solidifying North America's dominance in the market. For instance, according to the Tebra Inc. in 2024, approximately 71 million Americans have high cholesterol, and although there are many potential causes, one key factor is that certain habits can raise cholesterol levels without people even realizing it. Furthermore, the integration of innovative technologies like point-of-care testing devices and digital health solutions has contributed to the region's leadership in cholesterol monitoring.

Competitive Landscape

The major global players in the cholesterol testing products market include Abbott Laboratories, F. Hoffmann-La Roche AG, Siemens Healthineers GmbH, ACON Laboratories Inc., Lepu Medical Technology (Beijing)Co., Ltd., SD Biosensor, INC., Recombigen Laboratories Pvt. Ltd, Assure Tech (Hangzhou) Co., Ltd., V.P. Healthcare and SG Diagnostics among others.

Key Developments

• In August 2024, AstraZeneca's Imfinzi (durvalumab) received approval in the United States for use in combination with chemotherapy to treat adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) who do not have known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
• In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have a BRAF V600E mutation, as identified by an FDA-approved test. This approval provides a new personalized treatment option for patients with this specific mutation in their cancer.
• In August 2023, Eli Lilly and Company announced the topline results from the LIBRETTO-431 study, which evaluated Retevmo (selpercatinib) against platinum-based chemotherapy plus pemetrexed as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC).

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Cholesterol Testing Products Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Test Type
• 3.3. Snippet by Application
• 3.4. Snippet by End User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Advancements in Research and Development
  • 4.1.2. Restraints
    • 4.1.2.1. High Costs of Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
  • 6.1.2. Market Attractiveness Index, By Product
• 6.2. Devices*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Test Kits
• 6.4. Others

7. By Test Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 7.1.2. Market Attractiveness Index, By Test Type
• 7.2. Total Cholesterol Tests*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Low Density-Lipoprotein (LDL) Cholesterol Tests
• 7.4. High-Density Lipoprotein (HDL) Cholesterol Tests
• 7.5. Triglycerides Tests
• 7.6. Others

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Cardiovascular Diseases*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Diabetes
• 8.4. Obesity
• 8.5. Hyperlipidemia
• 8.6. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Diagnostic Centers
• 9.4. Home Healthcare
• 9.5. Research Laboratories

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

• 12.1. Abbott Laboratories*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. F. Hoffmann-La Roche AG
• 12.3. Siemens Healthineers GmbH
• 12.4. ACON Laboratories Inc.
• 12.5. Lepu Medical Technology (Beijing)Co., Ltd.
• 12.6. SD Biosensor, INC.
• 12.7. Recombigen Laboratories Pvt. Ltd
• 12.8. Assure Tech (Hangzhou) Co., Ltd.
• 12.9. V.P. Healthcare
• 12.10. SG Diagnostics
• Similar data will be provided for each market player.

Emerging Market Players

• 12.11. Processa Pharmaceuticals, Inc.*
  • 12.11.1. Pipeline Products Description
  • 12.11.2. Product Key Performance Indicators (KPIs)
  • 12.11.3. Key Activities
  • 12.11.4. Market Entry Timelines
  • 12.11.5. Product Penetration Rate
  • 12.11.6. Sales Estimation and Projections
• 12.12. Vanda Pharmaceuticals Inc.
• 12.13. Renexxion Ireland Limited
• 12.14. Aclipse Therapeutics
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us